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Subunit vaccines are safer but less immunogenic than live-attenuated vaccines or 
whole cell inactivated vaccines. Adjuvants are used to enhance and modulate antigen 
(Ag) immunogenicity, aiming to induce a protective and long-lasting immune response. 
Several molecules and formulations have been studied for their adjuvanticity, but 
only seven have been approved to formulate human vaccines. Metallic nanoparticles 
(MeNPs), particularly those containing gold and iron oxides, are widely used in medi-
cine for diagnosis and therapy and have been used as carriers for drugs and vaccines. 
However, little is known about the immune response elicited by MeNPs or about their 
importance in the development of new vaccines. There is evidence that these particles 
display adjuvant characteristics, promoting cell recruitment, antigen-presenting cell 
activation, cytokine production, and inducing a humoral immune response. This review 
focuses on the characteristics of MeNPs that could facilitate the induction of a cellular 
immune response, particularly T-helper 1 and T-helper 17, and their potential functions 
as adjuvants for subunit vaccines.
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iNTRODUCTiON
Adjuvant selection for subunit vaccines is a key to increasing immunogenicity and, therefore, guiding 
stimulation of innate immunity and the development of the appropriate protective response to combat 
the microorganism of interest. Adjuvants are classified as particulate formulations, immunomodula-
tory molecules, or a combination of both characteristics. In addition to acting on the diversity of 
the humoral and cellular immune response, they can act in several different ways: by decreasing 
the vaccine dose, accelerating the immune response, or prolonging the immune response (1, 2). 
Among the seven approved vaccine adjuvants for human use, aluminum salts (alum), emulsions 
(e.g., MF59), and virosomes are particulate formulations. While alum induces efficient antibody (Ab) 
production and a predominant T-helper 2 (Th2) response, the other two have the capacity to induce 
T-helper 1 (Th1) and Th2 as well as Ab. Adjuvant system (AS) 01 and 04 used the combination of 
an immunomodulatory molecule and a particulate formulation composed of a Toll-like receptor 4 
(TLR4) agonist, monophosphoryl lipid A that also induces Ab. The incorporation of alum in AS04 
improved the humoral response, while the association of saponin (QS-21) and liposome in AS01 
favored Th1 responses (3, 4). Imidazoquinolines (TLR7 and TLR8 agonists) and lipid A analogs 
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(TLR4 agonists) are immunomodulatory molecules, capable of 
generating a Th1 response (5).
There is a demand for safe adjuvants capable of inducing 
efficient cellular immunity, especially Th1 and Th17, to be used 
against tuberculosis, leishmaniasis, malaria, and other diseases 
caused by intracellular microorganisms (1, 6). The majority of 
molecules with this type of adjuvanticity (Th1 driven) are related 
toward the response of danger receptors to trigger inflammation, 
thus safety and tolerance could be major barriers that prevent 
their use in human vaccines (7). However, comparing Alum and 
CpG/DNA adjuvants in human trials, only common adverse 
effects, including local site reaction, flu-like symptoms and 
headache were observed when CpG/DNA was used (8). Also, 
Verstraeten et  al. (9), analyzing more than 30,000 individuals, 
who received vaccine-containing AS01, observed that only com-
mon side effects occurred.
Nanoparticles (NPs) are classically described as structures 
smaller than 100 nm and can be classified, based on their com-
position, as polymeric, inorganic, liposomes, immunostimulating 
complexes, virus-like particles, emulsions, or self-assembled pro-
teins (10). They are made of different materials and differ in size, 
shape, and surface properties; interactions with biological systems, 
therefore, are varied, with several applications in modern medi-
cine. In vaccinology, they are classically thought to have delivery 
and deposit properties. However, many NPs have been shown to 
stimulate immune responses, including cell recruitment, activation 
of antigen (Ag)-presenting cells (APCs), and induction of cytokine 
and chemokine release. The development of nanostructures and 
nanoadjuvants may therefore offer alternatives to currently used 
adjuvants once studies establish ways for them to elicit innate 
immune response and support the development of adaptive 
immune response in the context of vaccine formulations (10).
Metallic nanoparticles (MeNPs) are relatively non-biode-
gradable, have rigid structures, and possess simple synthesis 
methodology. Many have been studied for their immunological 
properties (11). However, there are still gaps in understanding 
the immune response generated by NPs, especially MeNPs. Few 
studies have compared NPs of different types and there is no 
standardization among published methodologies, which ham-
pers comparisons of immunostimulatory characteristics. Several 
important characteristics, therefore, have not been well studied. 
For example, how chemical and physical properties (including 
material composition, size, shape, surface charge, and hydropho-
bicity) impact vaccine immune response (5). This review focuses 
on the use of MeNPs in formulations against infectious diseases, 
aiming to assess progress of their use in vaccinology and their 
possible applications as adjuvant.
THe iMMUNe ReSPONSe GeNeRATeD 
BY MeNP-FORMULATeD vACCiNeS
Table 1 summarizes the articles that report the use of MeNPs as 
part of vaccine formulations against infectious diseases and the 
immune responses they elicited. A range of immune responses is 
required to fight a diverse group of microorganisms. The type of 
protective immune response can be simplistically divided based 
on the type of microorganism: extracellular bacteria and toxin, 
intracellular bacteria, viruses, fungi, and protozoa. Among the 
vaccines targeting extracellular bacteria and toxin, two were 
formulated with lipopolysaccharide (LPS) in glycopeptide Ag. 
The use of glycoantigen and LPS can trigger an intense response 
through TLR4 and B  cell receptor activation; the presence of 
gold NPs (AuNPs) may have minimal influence on this response. 
However, in the work of Gregory et  al. (12) and Torres et  al. 
(13), the use of AuNPs in the formulation generated a different 
response, improving anti-LPS immunoglobulin G (IgG) response, 
decreasing bacterial burden, generating a more efficient humoral 
response, and improving animal survival, showing that AuNPs 
may influence immune response and protection.
Using protein Ag, Barhate et al. (22) formulated a vaccine using 
AuNPs and toxoid Ag and demonstrated that their formulation 
could induce a mucosal and systemic IgG and IgA response. When 
co-administered with Asparagus racemosus extract, a botani-
cally derived adjuvant, the response was further enhanced (22). 
Dakterzada et al. (24) developed a vaccine against Pseudomonas 
aeruginosa using the flagellin subunit and AuNPs that elicited an 
IgG response comparable to that induced by Freund Adjuvant. 
Flagellin is a TLR5 agonist but the recognition and signaling is 
structure dependent. This study, however, used only the 1–161aa 
from flagellin and its ability to activated TLR5 could not be 
maintained (24). Gregory et al. (12) used an F1 Yersinia pestis Ag 
conjugated to AuNPs that induced an Ab response with higher 
IgG2a associated with higher levels of interferon gamma (IFNγ), 
suggesting activation of Th1 cells.
Among the studies that used MeNPs in vaccine formulation, 
only one targeted intracellular bacteria (Listeria monocytogenes). 
The protective immune response against intracellular bacterial 
infections requires Th1 activation and, therefore, APCs activation 
and Ag presentation through major histocompatibility complex 
II (MHC II). To generate a Th1 response, an AuNP and Listeria 
Ag formulation were used in different strategies. Although the 
authors tested direct vaccination, when dendritic cells (DC), 
in  vitro loaded with AuNP plus Listeria Ag, were adoptively 
transferred to a naïve animal, they induced Th1, CD8+, and 
natural killer (NK) cells that provided better protection against 
L. monocytogenes than the traditional vaccine approach (23).
In evaluating vaccines developed with MeNPs against viral 
infections, Niikura et al. (20) used West Nile virus (WNV); Tao 
et al. (21) used the extracellular portion of Matrix 2 protein (M2) 
of the influenza virus; Chen et al. (15) conjugated AuNPs with 
a 28 amino acid VP1-foot-and-mouth virus protein (pFMDV); 
and Staroverov et al. (17) co-administered AuNPs and partially 
purified enteropathogenic swine-transmissible gastroenteritis 
virus. All the above studies evaluated the Ab immune responses 
and all formulations demonstrated efficient humoral response 
induction. Tao et al. (21) also evaluated the addition of cytosine 
and guanine linked by phosphodiester unmethylated (CpG/
DNA) and found that it improved Ab levels and animals’ survival 
rates. Another important feature of studies by Niikura et al. (20) 
and Chen et al. (15) was the use of various NP sizes and the dem-
onstration that all different NP shapes were capable of inducing a 
humoral response. The levels of Ab were size dependent, but the 
results were inconsistent: the first study found that a 40 nm sphere 
TABLe 1 | Studies describing immune responses to vaccination with metallic nanoparticles, listed by NPs material and year of publication (n = 18 studies).
NP 
material
Complementary 
adjuvant
Animal model (route of vaccination) evaluation of immunogenicity Reference
Gold C57BL/6 (H-2b) and BALB/c (H-2d) mice used for 
protection experiments (intraperitoneal)
CD4+, IL-2+, and duration and avidity of total 
immunoglobulin G (IgG) (IgG1, IgG2a, IgG2b, and IgG2c)
Kaba et al. (14)
BALB/c mice (intraperitoneal and subcutaneous) IgG (total) Chen et al. (15)
Alum, CFA/IFA BALB/c mice (subcutaneous) IgG1, IgG2a, IgG2b, and IgG3 Parween et al. (16)
Albino mice and rabbits (intraperitoneal) IgG, circulant IFN-γ, and ROS in vivo generation by 
peritoneal macrophages
Staroverov et al. (17)
Alhydrogel BALB/c mice (intramuscular) IgG1 and IgG2a titer, CD4 and CD8 activation, and IFN-γ 
release
Gregory et al. (12)
C57BL/6 (H-2b) and BALB/c (H-2d) mice used 
for protection experiments (intramuscular/
intraperitoneal)
Total IgG, IgM and IgA titer and avidity, and CD8+ memory 
population (effector, central, and long-term central)
Kaba et al. (18)
C57BL/6 mice (intramuscular/intraperitoneal) IgG1, IgG2c, IgG3, and IgE titers Mccoy et al. (19)
C3H/HeNJc1 mice (intraperitoneal) IgG Niikura et al. (20)
CpG/DNA (TLR9 
agonist)
BALB/c mice (intranasal) IgG1 and IgG2a Tao et al. (21)
Asparagus 
racemosus extract
Swiss albino mice (oral) Serum IgG, serum IgA, intestinal IgA, and fecal IgA Barhate et al. (22)
LPS (TLR4 agonist) BALB/c mice (intranasal) IgG1 and IgG2a Gregory et al. (12)
LPS (TRL4 agonist) Rhesus macaques (subcutaneous) IgG Torres et al. (13)
Advax™ adjuvant BALB/c mice (intraperitoneal and intravenous) T-helper 1, CD8+, and NK cells Rodriguez-Del Rio 
et al. (23)
BALB/c mice (subcutaneous) IgG (total) Dakterzada et al. (24)
Iron SW mice (intraperitoneal, intramuscular, and 
subcutaneous), Aotus lemurinus trivirgatus 
monkeys (intramuscular)
Total Ab response, IFN-γ, and IL-4 (mice) and total Ab 
response (monkeys)
Pusic et al. (25)
Nickel BALB/c mice (subcutaneous) IgG response Fischer et al. (26)
BALB/c mice (subcutaneous) IgG1 and IgG2a serum titer and IL-12/p40 and RANTES/
CCL5 serum concentration
Wadhwa et al. (27)
BALB/c mice (subcutaneous) Specific serum IgG, IgG1 and IgG2a Ab titers and IFN-γ 
(splenocytes)
Yan et al. (28)
Ab, antibody; Alum, aluminum salts; CFA, complete Freund adjuvant; IFA, incomplete Freund adjuvant; IFN, interferon; Ig, immunoglobulin; IL, interleukin; LPS, lipopolysaccharide; 
NK, natural killer; NP, nanoparticle; ROS, reactive oxygen species; SW, Swiss Webster mouse; Th, T-helper; TLR, Toll-like receptor.
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was the most efficient Ab inducer and the second study found that 
the 8 nm and 12 nm spheres performed best.
A special case of the use of MeNPs was the use of nickel-
functionalized nanolipoprotein particles (NiNLPs) by Yan 
et  al. (28) and Wadhwa et  al. (27) in combination with HIV 
Ag. NiNLPs are nanometer-sized nanolipoprotein particles 
with nickel incorporation into their surface in order to induce 
polyhistidine tagged proteins adsorption (29). They demon-
strated that specific IgG (IgG1 and IgG2a) levels were greater 
than those obtained when alum was used in the formulation. 
Fischer et  al. (26) used truncated WNV envelope protein Ag 
and found that a single dose vaccination induced a superior 
anti-WNV IgG response and improved protection against a 
WNV challenge (26). These responses were associated with 
nickel functionalization, described as a hapten, and triggered 
responses through activation of human TLR4 and intracellular 
transduction signals through myeloid differentiation primary 
response (MyD-88), nuclear factor-κB (NF-κB), and mitogen-
activated protein kinase (MAPK), inducing pro-inflammatory 
responses [tumor necrosis factor (TNF)-α and interleukin 
(IL)-8] (30, 31).
For protozoan infections, Parween et  al. (16), using 
Plasmodium falciparum merozoite surface protein subunit 
and AuNPs, evaluated the humoral immune response (IgG1, 
IgG2a, IgG2b, and IgG3) and found an intense IgG1 response 
compared with the alum formulation (16). Kaba et  al. (14), 
using P. berghei circumsporozoite protein and AuNPs, gener-
ated long-lasting protective immunity with Th that produced 
IL-2 and mixed high avidity IgG1/IgG2a (Th2/Th1) (14). In 
other studies, these authors replaced Ag with P. falciparum 
circumsporozoite protein; vaccination was shown to induce 
protective cytotoxic (CD8+) cells, high avidity Ab titers, and 
specific effector memory, central memory, and long-term 
central memory CD8+ T  cells in draining lymph nodes, 
spleen, and liver (18). This response was shown to be gener-
ated by DC cross-presentation, which had delayed fusion and 
interaction of endosomes with lysosomes caused by the AuNP 
formulation (19). Finally, PfMSP was used with dextran-
coated iron oxide NPs (IONPs) and was capable of inducing 
a humoral response in two animal models (mouse and mon-
key). This response was also shown to inhibit parasite growth 
by 55–100% (25).
FiGURe 1 | important nanoparticle characteristics for adjuvanticity. To be recognized and to stimulate innate immunity, metallic nanoparticles (MeNPs) must 
have some physicochemical traits that allow for interactions with host cells and lead to the generation of a response. APCs, antigen-presenting cells; MeNPs, 
metallic nanoparticles; Th, T-helper cell.
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Most studies evaluated immunogenicity through measure-
ment of the humoral immune response. According to their 
findings, the use of NPs was efficient in inducing an Ab-based 
response. Based on heavy chain structure, there are five types of 
Ab, each with a different role: IgG, IgM, IgA, IgD, and IgE. IgG 
and IgA can be subdivided as IgG1, IgG2, IgG3, IgG4, IgA1, and 
IgA2 based on additional small differences in their heavy chain. 
With regard to vaccination, humoral immunity is especially 
important in responding to infection by extracellular pathogens, 
toxins, protozoa, and viruses. Its importance is associated with the 
biological activities of immunoglobulins, including microorgan-
ism opsonization and phagocytosis; complement activation (32); 
toxins and microorganism neutralization (33); and mast cells and 
basophil activation (32, 34). In addition, immunoglobulins can 
help target cytotoxicity against infected cells (Ab-dependent cell 
cytotoxicity of CD8 T cells and NK). In some cases, however, the 
pathogens have the ability to evade the humoral system or can 
even use immunoglobulins as a way to facilitate cell invasion, as 
in the cases of Mycobacterium tuberculosis and Leishmania spp. 
(35, 36).
The studies described above clearly show that MeNPs 
(gold, iron, and nickel) can be used for vaccine development. 
Different MeNPs were used in conjunction with several Ag for 
distinct microorganisms and showed the ability to generate 
humoral and cytotoxic responses. Although the generation of 
IgG2a and IFN-γ shown in some studies are indicators of Th1 
responses using MeNPs as adjuvant, further research is needed 
to specifically assess the role of different MeNP vaccines in Th1 
induction.
iMPORTANT PHYSiCOCHeMiCAL 
CHARACTeRiSTiCS OF MeNPS AS 
ACTivATORS OF iMMUNe ReSPONSeS
To understand the possible uses of MeNPs as platforms for 
vaccines against infectious diseases, analysis is needed of the 
impact of different physicochemical characteristics of NPs on 
the innate immune response (Figure 1). Several strategies have 
included MeNPs as vaccine platforms, involving MeNPs of dif-
ferent materials (including gold, iron oxide, and nickel); shapes 
(including spheres, cubes, rods, and disks); sizes (from 2 nm to 
over 200 nm); and types of coating [e.g., citrate, chitosan, dextran, 
or cetyltrimethylammonium bromide/4-styrenesulfonic acid-co-
maleic acid (CTAB/PSS-MA)].
The material from which an NP is made has a direct influ-
ence on the functions of APCs; gold NPs (AuNPs) have been 
most commonly used in vaccinology (Table 2). The most recent 
studies involving AuNPs demonstrate the effects of gold sodium 
thiomalate on macrophage function, showing lysosomal enzyme 
inhibition and reducing phagocytosis (37). Similar effects were 
seen in macrophages of several origins, which, when stimulated 
with AuNPs, showed diminished bactericidal activity against 
Staphylococcus aureus (38) and low or absent cytokine produc-
tion IL-6, IL-10, and TNF-α (39, 40). Moreover, when splenocytes 
were stimulated with LPS, the addition of AuNP reduced IL-17 
and TNF-α release (40). Some of these results raise the concern on 
the use of AuNPs as adjuvants, since these immunomodulatory 
properties can act inhibiting the generation of Th1. However, the 
response to AuNPs is also correlated with other physicochemical 
TABLe 2 | Studies describing NPs and antigens used as vaccines against infectious diseases, listed by NPs material and year of publication (n = 18 
studies).
NP material Size in nm (shape) Functionalization Antigen (microorganism) Reference
Gold 25 (sphere) P. berghei circumsporozoite protein (Plasmodium berghei) Kaba et al. (14)
2, 5, 8, 12, 17, 27, 32, and 50 
(sphere)
Citrate pFMDV (foot-and-mouth virus) Chen et al. (15)
17 (sphere) Citrate PfMSP-119 (P. falciparum) Parween et al. (16)
15 (sphere) Citrate Partially purified enteropathogenic STG coronavirus Staroverov et al. (17)
15.6 (sphere) Citrate F1-antigen (Yersinia pestis) Gregory et al. (12)
40 (sphere) Pf CSP (P. falciparum) Kaba et al. (18)
35–40 (sphere) Citrate Pf CSP (P. falciparum) Mccoy et al. (19)
20 and 40 (sphere), 40 × 10 
(rod), and 40 × 40 × 40 (cubic)
CTAB and PSS-MA WNVE protein (WNV) Niikura et al. (20)
12 (sphere) Citrate Extracellular portion of M2 protein (influenza virus) Tao et al. (21)
40 (sphere) Chitosan Tetanus toxoid bulk from Clostridium tetani Barhate et al. (22)
15 (sphere) Citrate TetHC and modified LPS from Clostridium tetani Gregory et al. (12)
15 (sphere) Citrate LPS conjugated to FliC as glycoantigen (Burkholderia thailandensis) Torres et al. (13)
1.5 (sphere) T cell epitopes, LLO91–99, and LLO189–201 (Listeria monocytogenes) Rodriguez-Del Rio et al. (23)
15 (sphere) Citrate Flagellin1-161 (Pseudomonas aeruginosa) Dakterzada et al. (24)
Iron 20 (sphere) Dextran PfMSP-11-42 (P. falciparum) Pusic et al. (25)
Nickel 23 (discoidal) Truncated WNVE protein (WNV) Fischer et al. (26)
199, 214, and 270 (capsule) Gag p41 (HIV) Wadhwa et al. (27)
100 (capsule) Gag p41 or p24/his-Nef (HIV) Yan et al. (28)
CTAB, cetyltrimethylammonium bromide; HIV, human immunodeficiency virus; LPS, lipopolysaccharide; NP, nanoparticle; Pf CSP, P. falciparum circumsporozoite protein; pFMDV:; 
PfMSP, P. falciparum merozoite surface protein; PSS-MA, poly(4-styrenesulfonic acid- comaleic acid); STG, swine-transmissible gastroenteritis; TetHC, Hc fragment (TetHc) of 
tetanus toxin; WNV, West Nile virus; WNVE, WNV envelope.
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characteristics that will be discussed below, which may be tailored 
to improve immunostimulatory or immunomodulatory capacity.
Iron oxide nanoparticles have also been used as adjuvants. 
Iron is an important ion in the homeostasis of all cells and in gen-
erating immune responses to several microorganisms. The effect 
of IONPs phagocytosis have been explored in several studies, 
for example, M2 macrophages after exposure to IONPs induced 
reactive oxygen species (ROS), but after 24 h induced IL-10 pro-
duction (41). The use of IONPs in BALB/c mice demonstrated 
the immunomodulatory capacity of this NP by diminishing 
splenocyte cytokine production (IL-4 and IFN-γ) (42) as well as 
suppressing the response to pancreatic Ag in diabetic mice (43). 
Sindrilaru et al. (44), however, showed that macrophages, under 
iron overloaded conditions, became unrestrained M1 (with an 
incomplete switch to M2 macrophages) and produced more 
TNF-α, which impaired wound healing and had an important 
role in the immunopathology of chronic venous leg ulcers. 
Consequently, IONP response seems to have direct correlation 
with time and dose, once iron overload seems to be a requisite to 
developed pro-inflammatory response and this aspect must be 
evaluated to avoid the inhibition of the desired immune response.
Other critical characteristics are the shape and size of NPs, 
which have a direct impact on vaccine efficiency, Ag load capacity, 
and interaction with cells (phagocytes and APCs). These character-
istics have been studied in different NPs; Shah et al. (45) published 
a review focusing on the impact of size for alum, oil-in-water, 
emulsion, polymeric particles, and liposome adjuvanticity, but did 
not evaluated MeNPs. In the studies reviewed here, NP sizes range 
from 2 nm nanospheres to 270 nm nanocapsules. Two authors 
have evaluated the impact of size and shape for MeNPs (Table 2): 
Chen et al. (15) evaluated differences in immune response based 
on AuNP sizes (ranging from 2 to 50 nm nanospheres) and found 
that 8 and 12 nm were the most drained NP (15); Niikura et al. 
(20) went further and, using four different shapes of NP (20 nm 
sphere, 40 nm sphere, cube, and rod), showed that Ab responses 
and TNF-α were directly correlated with the specific NP surface 
area (the ratio of the total surface area per single NP volume). 
Furthermore, 40  nm spheres appear to be the most efficient in 
generating immune responses (IL-6 and IL-12) and granulocyte 
macrophage colony-stimulating factor production.
Surface charge and hydrophobicity are additional important 
NP characteristics for immune response induction and are 
directly influenced by NP functionalization (chemical modifica-
tion of NPs surface by adding or replacing functional groups) 
and coating (Ag) (46). Most studies used citrate-coated NPs, but 
dextran and CTAB/PSS-MA have also been used; all three result 
in negatively charged (anionic) particles. Only one NP, revised 
here, used positive charged (cationic) functionalization [(22); 
Table 2]. The higher hydrophobicity of AuNP was shown to acti-
vate the innate immune system (TNF-α secretion) (47). Although 
the surface charge of other non-metallic NPs has been studied 
(48), to our knowledge the studies using MeNPs did not address 
the other characteristics associated with immune response induc-
tion. For non-metallic NPs, it appears that a positive charge signi-
fied a greater ability to induce immune responses than a negative 
charge. Interestingly, negatively charged non-metallic NPs were 
associated with Ag-specific tolerance (48). Further studies are 
needed to investigate whether or not the charge imputed by NP 
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coating influences the immune response. Though the size and 
shape of MeNPs had little to no impact on the innate response 
elicited, coating modifications may improve the capacity of these 
molecules to influence immune responses. Finally, it is important 
to note that the majority of adjuvant characteristics were evalu-
ated using non-metallic NPs.
NPs AS ADJUvANTS TO GeNeRATe Th1 
and Th17 ReSPONSeS
T-helper 1 cells are associated with immunity against intracel-
lular pathogens and the secretion of IFN-γ, which, in turn, is 
essential for the activation of mononuclear phagocytes, includ-
ing macrophages, resulting in enhanced phagocytic activity (49). 
Th17  cells (IL-17A and IL-17F producer cells) are associated 
mainly with stimulation and chemotaxis of neutrophils to the 
site of inflammation. However, their function goes beyond this 
and includes the targeting of various cells types, including non-
lymphoid cells and the stimulation of cytokine, chemokine, and 
prostaglandin production. Another characteristic of these cells 
is their memory effector subset, which is maintained in mucosal 
tissues for extended periods. This subset has high plasticity and 
is able to transform into Th1 or Th2 phenotypes depending on 
the cytokine milieu at mucosal sites. This diversity of function 
and actuation make Th17 cells very important in defense against 
several microorganisms, mainly those acquired through mucosal 
routes (49, 50).
T-helper 1 and Th17 cells have their own distinct sets of func-
tions and differentiation factors. Both cell types require T  cell 
receptor downstream activation by Ag presentation cells through 
MHC II and co-stimulatory molecules (6). Consequently, 
cytokine release during Ag presentation is correlated with the 
type of adaptive immune response generated. While Th1 differ-
entiation requires stimulation by IL-12, Th17 generation requires 
transforming growth factor-β and IL-6. However, this generation 
is influenced by other factors and how MeNP are involved in the 
possible induction of Th1 or Th17 will be discussed below.
In this review, only one study investigated the development of 
the direct Th1 (type 1 T helper cell) and Th17 response. Using a 
Listeria Ag, Rodriguez-Del Rio et al. (23) showed that in contrast 
to Advax™ adjuvant alone, a combination of 25 nm AuNPs and 
Advax™ was capable of inducing the highest Th1 response. Pusic 
et al. (25) immunized mice with IONPs covered with rMSP1, a 
P. falciparum merozoite Ag, and showed that after immunization 
(intramuscular, subcutaneous, or intraperitoneal), production of 
IL-4 was greater than that of IFN-γ, suggesting a predominant 
Th2 response (although the cellular immune response was not 
directly evaluated).
The first major determinant in generating Th1 and Th17 
populations is the route of vaccine administration, which dictates 
the cell dynamic and initial response to the vaccine. For example, 
Mohanan et al. (51), in a cross-sectional study using a liposome 
plus Ag (OVA) vaccine formulation, compared intradermal (high 
IgG1; intermediate IgG2; and IFN-γ), intralymphatic (high IgG1, 
IgG2, and IFN-γ), intramuscular (high IgG1; intermediate IgG2 
and IFN-γ), and subcutaneous (high IgG1; low IgG2 and IFN-γ) 
routes of administration (51). The predominant Th1 response to 
administration through the intradermal route was most likely due 
to the cooperation between Langerhans cells, the primary innate 
immune response cells and keratinocytes that may also be stimu-
lated by the formulation. These elicited the production of cytokines 
and chemokines that helped in the activation of other APCs (52).
The early phase of vaccination is characterized by recruit-
ment of neutrophils and monocytes to the site of inoculation. 
Both cell types can also act as APCs, delivering Ag-specific and 
co-stimulatory signals to T  cells. Their collaborative endeavors 
have been found to modulate (positively or negatively) the activ-
ity of different effector T  cell subsets (53, 54). Neutrophils are 
the first cell lineage to migrate to inflammation sites and, when 
stimulated, they produce cytokines and chemokines that will 
attract and activate other cell types. For example, neutrophils 
were shown to be an important inducer of Th1 and Th17 cells 
(55), but their role in cytokine secretion is much broader (56). 
Moreover, signals may elicit different function in neutrophils and 
therefore, influence the quality of T cell responses. For example, 
AuNPs have been described as capable of inducing neutrophil 
extracellular traps, which act as damage-associated molecular 
patterns and stimulate immune system through DNA receptors 
such as TLR9 (57). Upon stimulation by NPs (TiO2—titanium 
dioxide—and alum), Duffin et al. (58) demonstrated neutrophil 
influx to the lungs and also induced production of IL-18. Silver 
NPs were also shown to be capable of interacting with neutro-
phils, inducing apoptosis of these cells, and inducing caspase-1\
caspase-4 partially dependent IL-1β secretion (59). In another 
study, cobalt and nickel NPs were shown to induce higher nitric 
oxide, TNF-α, and CXCL2 chemokine production, by human 
peripheral blood neutrophils, than titanium NPs (TiO2NP) (60). 
Nonetheless, TiO2NPs also induced polymorphonuclear cell 
activation through phosphorylation of several proteins, including 
p38 MAPK and extracellular signal-regulated kinases-1/2 (Erk-
1/2), which were associated with increased neutrophil life-span 
and production of several cytokines and chemokines (61).
Classically, APCs, macrophages, and DCs act at the site of 
vaccine inoculation by sensing foreign agents, through TLRs and 
other receptors, and triggering inflammation. APCs play a key 
role in the initiation, maintenance, and selectivity of inflamma-
tion, through their three major functions: endocytosis, Ag pres-
entation, and production of various cytokines and growth factors 
(1). The main family of pattern recognition receptors in microbial 
recognition is the TLRs, part of the family of transmembrane 
proteins, which affect the transcription of genes involved in 
inflammatory and immune response-enhancing cellular activi-
ties such as phagocytosis, endocytosis, cytotoxic functions, and 
cytokine production (62, 63).
The adjuvants most frequently used for the induction of 
Th1 and Th17 responses are TLR agonists, such as AS04, CPG/
DNA, and others. MeNPs seems to have capacity to induce the 
expression of Toll-like receptors, such as TiO2NPs and zirconium 
oxide NPs that have been described to enhance TLR3, TLR7, and 
TLR10 expression in macrophages (64) and TLR2 and TLR4 in 
mouse liver cells (65). Zinc oxide NPs (plus OVA) generated an 
inflammatory response in BALB/c mice and also improve TLR-2, 
-4 and -6 expression, followed by activation of Src family kinases 
(66). Consequently, TiO2NPs and IONPs were shown to induce 
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DC upregulation of co-stimulatory molecules (MHC II, CD80) 
(25, 67, 68), which can also be related to TLR stimuli pathways. 
However, none of these works demonstrate the direct interaction 
of NPs with TLR (using Knock-out mice, agonists, or antagonist 
molecules) thus, this interaction must be further studied.
The next step in the generation of adaptive responses is the tai-
loring of cytokine secretion by APCs at immunological synapses, 
which will guide the development of the response. Several NPs 
have been reported to trigger cytokine and chemokine produc-
tion, which may be used as biomarkers for immunotoxicity (69). 
Among those described, TiO2NPs were used in mimetic systems 
composed of blood vein endothelial component (including 
PBMC) and was reported to trigger pro-inflammatory cytokines 
(IL-6, IFN-γ, and TNFα) (67); Zinc oxide NPs were shown to 
be preferentially associated with monocytes and, when used in 
PBMC, induced IFN-γ, TNF-α, and IL-12 cytokine production 
(70); AuNP-stimulated bone marrow-derived DC produced IL-6, 
TNF-α, and IFN-γ (20); and IONPs were shown to induce the acti-
vation of APCs with an increase of IL-6, TNF-α, IFN-γ, and IL-12, 
as well as chemokines. The response generated by IONPs, however, 
was weaker than that generated by the positive control LPS which 
may be beneficial in controlling possible side effects (25).
The generation of a cellular response associated with protection 
against intracellular pathogens is the ultimate goal of vaccination. 
However, the direct effects of NPs on cellular responses have 
been evaluated in only a few studies. TiO2NPs were shown to 
activate and induce proliferation of naïve CD4+ T cells and to 
generate a pronounced Th1 response with IFN-γ and TNF-α 
production, associated with pro-inflammatory cytokine produc-
tion (IL-6, IL-1a, IL-1b) and DC maturation (CD86+ and CD83+ 
expressions increase). Schanen et al. (71) hypothesized that the 
oxidative capacity of an NP could impact the response and trigger 
pro-inflammatory (oxidant capacity) or anti-inflammatory (anti-
oxidant capacity) responses. This oxidant effect could control 
ROS generation and thus control downstream pro-inflammatory 
effects while antioxidants prevent the initiation of the innate 
immunity in LPS-stimulated macrophages (71). This study was, 
however, conducted with mitogens (non-specific stimuli) and not 
with vaccine stimuli, but nevertheless serves as a warning about 
the direct action of NPs, not only on the innate immune system 
but specifically on T cells.
CONCLUSiON
There is enough evidence to suggest that MeNPs are not only 
particulate formulations but also immunostimulatory mol-
ecules with several studies demonstrating their capacity to 
generate humoral and cytotoxic responses. MeNPs clearly have 
FiGURe 2 | Metallic nanoparticles adjuvanticity and its prediction capacity to generate T-helper 1 (Th1) and Th17 responses. To generate a cellular 
immune response, the NP must be able to be recognized by the host innate immune response and stimulate a sequence of events that will lead to the release of a 
specific milieu of cytokines and better antigen presentation (bottom arrow). In the top arrow is the immune response elicited by metallic nanoparticles to aid Th1 and 
Th17 generation. NF-κB, nuclear factor kappa B; CCL, chemokine ligand; CXCL, chemokine (C-X-C motif) ligand; GM-CSF, granulocyte macrophage colony-
stimulating factor; IFN, interferon; IL, interleukin; M-CSF, macrophage colony-stimulating factor; MYD, myeloid differentiation factor; TCR, T cell receptor; Th, 
T-helper cell; TLR, Toll-like receptor; TNF, tumor necrosis factor.
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